Oxervate (cenegermin)
OrphanAccelerated assessment
- Region
- 🇪🇺 EU
- Active substance
- cenegermin
- Company
- Dompe' Farmaceutici S.p.A.
- Status
- Authorised
- Therapeutic area
- Keratitis
- CHMP opinion
- Thu 18 May 2017
- EU approval
- Thu 06 Jul 2017
- Designations
- Orphan, Accelerated assessment
- Application
- EMEA/H/C/004209
- ATC
- S01
- Official record
- www.ema.europa.eu
Indication
Treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults
Regulatory milestones
No milestones recorded in the last year.
Follow Oxervate
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.